In this article, we will take a look at the 5 Best Most Active Stocks to Buy Right Now. For a deeper discussion and an extended list, please see the 12 Best Most Active Stocks to Buy Right Now.
5. Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson (NYSE:JNJ) ranks among the best most active stocks to buy right now. On March 13, Johnson & Johnson (NYSE:JNJ) revealed results from a Phase 1 study of an innovative intravesical drug-releasing mechanism with erdafitinib (Erda-iDRS) in patients with non-muscle-invasive bladder cancer who had specific fibroblast growth factor receptor mutations.
According to the company, the trial met its major safety goals. The intermediate-risk sample of 62 patients had an 89% complete response rate, with a median length of 18 months.
Johnson & Johnson (NYSE:JNJ) also stated on March 12 that the FDA had approved its TECNIS PureSee IOL, an expanded depth of focus intraocular lens for cataract surgery. The lens is associated with JNJ’s TECNIS portfolio, which also includes the TECNIS Odyssey and TECNIS Eyhance IOLs. The company stated that millions of patients around the world receive TECNIS lenses each year as part of their cataract treatment.
Johnson & Johnson (NYSE:JNJ) is a diversified healthcare company. It operates through three main segments: Innovative Medicine, MedTech, and Consumer Health. Its product range includes pharmaceuticals and medical devices, as well as widely recognized consumer brands.
4. Abbott Laboratories (NYSE:ABT)
Abbott Laboratories (NYSE:ABT) ranks among the best most active stocks to buy right now. Following encouraging results from Abbott Laboratories (NYSE:ABT)’s FreeDM trial, Benchmark reiterated a Buy rating and $145 price target for the company’s shares on March 13. In comparison to individuals using whole blood glucose meters with fingerstick blood samples, the trial demonstrated that patients with Type 2 diabetes on basal insulin therapy who employed FreeStyle Libre continuous glucose monitoring technology achieved better glucose results.
The findings from the UK trial were supported by a second interventional trial from Italy delivered at the same conference. Both results emphasize the need for expanded insurance coverage of continuous glucose monitoring in European nations where Libre has not been officially covered.
Although no decision is expected very soon, the CMS is thinking about expanding compensation in the US. According to Benchmark, as one of the top providers of continuous glucose monitoring, Abbott Laboratories (NYSE:ABT) is well-positioned to profit from this development.
Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items.
3. UnitedHealth Group Incorporated (NYSE:UNH)
UnitedHealth Group Incorporated (NYSE:UNH) ranks among the best most active stocks to buy right now. On March 10, UnitedHealth Group Incorporated (NYSE:UNH) presented its strategic outlook at the Barclays 28th Annual Global Healthcare Conference, stressing growth, innovation, and operational improvements despite headwinds in certain areas of the business.
The company reiterated its forecast of over 8.5% growth this year and expects to produce a minimum of $18 billion in free cash flow. Management also intends to enhance dividends, cut debt, and maintain share buybacks, with the goal of achieving a debt-to-capital ratio of around 40% by the end of the year.
The company’s Optum Health posted a $600 million Q4 underperformance, attributed primarily to temporary issues and strategic initiatives. Meanwhile, Medicare Advantage bids are likely to grow by around 10%, indicating greater cost trends and risk modifications.
Looking ahead, UnitedHealth Group Incorporated (NYSE:UNH) is actively investing in AI through Optum Insight to improve healthcare efficiency and lower costs beginning in 2027.
UnitedHealth Group Incorporated (NYSE:UNH) is a renowned US multinational corporation that provides managed healthcare and insurance services. The company operates through four main segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx.
2. Netflix, Inc. (NASDAQ:NFLX)
Netflix, Inc. (NASDAQ:NFLX) ranks among the best most active stocks to buy right now. On March 12, Bernstein SocGen Group reiterated its Outperform rating and $115 price target for Netflix, Inc. (NASDAQ:NFLX). According to analyst Laurent Yoon, NFLX shares rebounded fast after the company withdrew from the contest for Warner Bros. Studio and streaming assets.
The discussion has returned to Netflix’s fundamentals and the possibility of upside in 2026 margins and EPS, although engagement issues and strategic options may limit short-term gains.
Netflix, Inc. (NASDAQ:NFLX) achieved roughly 600 basis points of margin growth in 2024 and 400 basis points in 2025, excluding the impact of Brazil. The streaming giant’s 2026 margin projection is 31.5%, representing a 50-basis-point increase over 2025, after accounting for the one-time Brazilian tax.
Meanwhile, Argus reduced its price target for Netflix, Inc. (NASDAQ:NFLX) to $110 from $141 while keeping a Buy rating on the stock. According to the firm, Netflix’s November 2022 announcement of a low-cost, advertising-supported subscriber plan was a stroke of genius as its advertising business rapidly scaled.
Netflix, Inc. (NASDAQ:NFLX) is a global entertainment company that offers a subscription-based streaming service featuring TV shows, movies, documentaries, and games.
1. Apple Inc. (NASDAQ:AAPL)
Apple Inc. (NASDAQ:AAPL) ranks among the best most active stocks to buy right now. On March 12, KeyBanc reaffirmed a Sector Weight rating on Apple Inc. (NASDAQ:AAPL), citing a 9% month-over-month fall in indexed spending data, which is lower than the three-year average of 4%. KeyBanc stated that the data is broadly in line with forecasts, with January and February figures having been somewhat mixed and providing little context for the quarter.
The firm stated that its projections are roughly on par with expectations for fiscal year 2026 and just below the consensus for fiscal year 2027 after updating its estimates to account for recent product releases.
KeyBanc stated that it’s less worried about gross margin strain than investors are, adding that it isn’t expecting a catalyst, with the share trading at its historical valuation.
Moreover, on March 5, Rosenblatt boosted its price target for Apple Inc. (NASDAQ:AAPL) to $268, citing the company’s product releases aimed at lower-end customers, including a Neo device for the Chromebook segment and a new iPhone 17e model.
Apple Inc. (NASDAQ:AAPL) engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables, and accessories, and other varieties of related services.
While we acknowledge the potential of AAPL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AAPL and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: Starter Stock Portfolio: 14 Safe Stocks to Buy Now and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
Hedge Fund Resource Center